CG Oncology (CGON) Cost of Revenue (2025 - 2026)

Name: CG Oncology (CGON) Cost of Revenue (2025 - 2026) | Business Quant
Creator: Business Quant

CG Oncology posted quarterly Cost of Revenue of $3.0 million for Q1 2026, down 3.52% on a QoQ basis from $3.1 million in Q4 2025.

CG Oncology (CGON) has 2 years of Cost of Revenue data on file, last reported at $3.0 million in Q1 2026.

For the quarter ending Q1 2026, Cost of Revenue changed N/A year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (changed N/A YoY), and the FY2025 full-year result was $4.6 million, changed N/A from the prior year.
Cost of Revenue for Q1 2026 stood at $3.0 million, down from $3.1 million in the prior quarter.
Across five years, Cost of Revenue topped out at $3.1 million in Q4 2025 and bottomed at $1.6 million in Q3 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	64.20 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	392.80 Mn
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	296.00 Mn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	207.52 Mn
10	CG Oncology	5.01 Bn	5.01 Bn	-1.88 Mn	2.96 Mn

Download Data 🔒